Baxter International (BAX) is back in focus after its latest earnings report showed higher quarterly sales and net income compared with last year, along with updated full year 2026 sales growth guidance of 3% to 4%.

Baxter International’s share price has risen strongly in recent months, with a 30 day share price return of 19.41% and a 90 day share price return of 51.57%, even though the 5 year total shareholder return is down 60.38%.

The recent earnings beat, higher sales, raised 2026 sales growth guidance and announced debt tender offer have helped shift market attention back to Baxter International, with the share price at US$26.95 despite a weaker 3 year total shareholder return of 31.84%.

If you are reassessing healthcare exposure after Baxter International’s move, it could be worth scanning other potential opportunities in the sector through the 43 healthcare AI stocks

Baxter International’s sharp rebound creates an obvious tension. Has the recent earnings beat, higher guidance and debt tender offer already done the heavy lifting for the stock, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 1.3% Undervalued

The most widely followed narrative currently places Baxter International’s fair value at $27.29, only slightly above the last close of $26.95, which points to a tight valuation gap built on detailed long term forecasts.

Baxter's strengthened focus on innovation, including new product launches in advanced infusion systems, AI-enabled devices, and compounding, aligns with growing demand for efficient, digitalized, and connected healthcare equipment, positioning the company to capture higher-margin revenue streams and gain market share.

The fair value hinges on a specific mix of steady revenue expansion, margin rebuild and a future earnings multiple that has to hold together over several years. The narrative leans on a clear path from current losses to consistent profits. Yet the exact growth glide path and profitability step up are where the real story sits.

Result: Fair Value of $27.29 (UNDERVALUED)

However, there are still clear risks to the Baxter International story if hospital IV fluid usage remains well below historical levels or if quality issues delay key infusion products.

Next Steps

The mix of risks and rewards around Baxter International can feel finely balanced, so it makes sense to review the numbers yourself and move promptly while sentiment is still shifting. To weigh both sides in one place, take a look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Baxter International?

If Baxter International has you rethinking your portfolio, do not stop here. The right screen can surface stocks you might otherwise miss.

• Target resilient businesses with strong financial foundations by scanning the solid balance sheet and fundamentals stocks screener (49 results).
• Spot potential value opportunities early by reviewing companies highlighted in the 49 high quality undervalued stocks.
• Hunt for lesser known opportunities with quality fundamentals using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.